RE:RE:RE:RE:Why grumble .... LABS is improving ....Australia was flat YoY and Canada was essentially the same. Personally I don't see $200k increases on $2.5m as material increases, when all the guidance we have ever been given is just wait until these new reg requirements make their way through the system. You can't decide to report Topline increases YoY and then decide to dig into the numbers to look for QoQ increases. End of day, revs went down when overall they should have gone up and there were lots of reasons, but none discussed and no solutions offered.
I agree that Germany was the biggest failure, and has been for years. That there is no guidance on that beyond, yippee, we did triple the business last quarter than all of last year, well gee whiz, the market was different last year wasn't it? 400k with Stada? That doesn't even pay for the Stada BD car allowance. Stada is not the horse in this race. Now it's more clear than ever.
Investor deck is all noise. They can put in that whatever they want, results matter, sales nonsense does not. New products in the US? Prove it and say what it is or it's nothing. For all we know, it's their big Remidose coming out party. The product that did all of a couple hundred grand somewhere and that could get traction on its own. Now the sales powerhouse Medipharm is going to take it to the promised land?
I mean, where are they with NDA/ANDA/505B2? I know where they are with ANDA, in legal limbo, but the others? No colour on that whatsoever. Same with Brazil.
The results were a massive L and the communication of them was moreso, if that's even possible.